Mayne Pharma shares surge on $407 mln takeover offer from Gedeon Richter
Mayne Pharma (ASX:MYX) accepted a A$604M ($407M) takeover offer from Gedeon Richter (BU:GDRB) at A$6.40 per share, a 99.4% premium. MYX shares surged 86.3%. The deal, pending approvals, is expected to close in March 2027. Richter aims to expand its U.S. presence in women's health.
How this was made
The 30-second read
Why it matters
The disclosed offer price, premium, funding source, and conditionality define the takeover-arbitrage setup and the key catalysts for spread compression or widening through approvals and the shareholder vote.
Market read
A large, premium all-cash takeover agreement with explicit timing for shareholder vote and targeted completion is a direct, tradable catalyst for MYX takeover-arb and risk management.
What to watch
Completion is contingent on multiple approvals (regulatory, shareholder, court) and Mayne’s prior international business sale to Evaris, any of which can extend timelines or introduce renegotiation risk.
Background
Mayne Pharma is an Australian pharmaceutical company; the article states it has agreed to a scheme implementation deed for an all-cash acquisition by Gedeon Richter.
Ticker impact
Mayne Pharma agreed to be acquired by Gedeon Richter for A$604 million, offering A$6.40 per share and a 99.4% premium.
Likely upward pressure as the market prices the takeover premium, tempered by deal-completion risk and any approval delays.
The article discloses a fully funded all-shares cash acquisition, board recommendation, and explicit premium, which are direct inputs to takeover-arb and risk pricing.
Market effects
Highlights consolidation appetite in pharma and may increase takeover-arb interest in other mid-cap pharma names with similar strategic fit.
Could boost sentiment toward Australian biotech/pharma risk assets as deal premiums attract arbitrage flows.
Reinforces Gedeon Richter’s US expansion narrative, potentially affecting how investors underwrite women’s health and specialty pharma M&A risk.
Counterpoint
The premium may not fully hold if regulatory approvals or the required Evaris sale condition becomes contentious, creating downside in deal-spread widening.
Key entities
- companyMayne Pharma
Subject of the takeover offer; agreed to be acquired for A$604 million at A$6.40 per share.
- acquirerGedeon Richter
Hungarian pharma buyer funding the acquisition from internal cash resources.
- transaction conditionEvaris Pharma
Mayne’s previously announced sale of its international business to Evaris is a condition to deal completion.



